克服开发和实施高血压新疗法的障碍
Konstantin A Krychtiuk1, Renato D Lopes1, Victoria A Cargill2
1Duke Clinical Research Institute, Durham, NC (K.A.K., R.D.L., J.B.G., N.J.P., A.F.H., C.B.G.).
Hypertension (Dallas, Tex. : 1979)
|August 28, 2025
概括
有效的高血压管理受到许多障碍的阻碍,但新的RNA向疗法和设备干预措施显示出克服这些挑战和改善心血管健康的希望.
科学领域:
- 心血管医学
- 药理学
- 生物技术
背景情况:
- 高血压是全球残疾和死亡的主要可修改风险因素,对弱势群体产生不成比例的影响.
- 尽管有有效的治疗方法,但血压控制仍然很低,最近的趋势表明血压正在下降.
- 系统性,患者相关和医疗保健提供者的障碍阻碍了高血压的有效管理.
研究的目的:
- 提供有效高血压治疗障碍的概述.
- 提供评估新型心血管疾病风险因素治疗的临床试验框架.
- 探索RNA向治疗和基于设备的干预等创新疗法的潜力.
主要方法:
- 对高血压管理障碍的现有文献的审查.
- 分析新型长效高血压治疗药物开发的挑战.
- 临床试验设计的框架开发,包括安全性,代用终点和护理标准.
主要成果:
- 确定了主要障碍,包括临床惯性,有限的健康素养,不遵守和报销问题.
- 突出了RNA向治疗和设备干预的潜力,以克服坚持障碍.
- 强调需要针对新型长效疗法的具体临床试验设计.
结论:
- 新型疗法有可能克服高血压治疗的重大障碍.
- 仔细考虑临床试验设计对于评估新的心血管风险因素治疗至关重要.
- 早期和广泛的实施计划对于将创新转化为改善患者结果至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Hypertension V: Nursing Management
42
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
42
Hypertension IV: Drug Therapy and Lifestyle Modifications
37
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
37
Hypertension II: Pathophysiology
77
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
77
Hypertension I: Introduction
72
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
72
Hypertension and Regulation of Blood Pressure
3.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.1K


